Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Duchemann

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The European Respiratory Journal|August 5, 2017
Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater ParisBoris Duchemann, Isabella Annesi-Maesano, Camille Jacobe de Naurois, et al.
Nature Medicine|February 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.
Nature Medicine|June 24, 2026
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Clinical Lung Cancer|July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer PatientsElisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.
JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Cancer Discovery|September 11, 2012
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Lauren Averett Byers, Jing Wang, Monique B Nilsson, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerJessica Menis, Laurent Greiller, Pierre Demontrond, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 7, 2025
[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique]Olivier Cravéreau, Vincent Bourbonne, Loïg Vaugier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 2, 2022
Airway replacement using stented aortic matrices: Long-term follow-up and results of the TRITON-01 study in 35 adult patientsEmmanuel Martinod, Dana M Radu, Ilaria Onorati, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The European Respiratory Journal|August 5, 2017
Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater ParisBoris Duchemann, Isabella Annesi-Maesano, Camille Jacobe de Naurois, et al.
Nature Medicine|February 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.
Nature Medicine|June 24, 2026
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Clinical Lung Cancer|July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer PatientsElisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.
JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Cancer Discovery|September 11, 2012
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Lauren Averett Byers, Jing Wang, Monique B Nilsson, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerJessica Menis, Laurent Greiller, Pierre Demontrond, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 7, 2025
[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique]Olivier Cravéreau, Vincent Bourbonne, Loïg Vaugier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 2, 2022
Airway replacement using stented aortic matrices: Long-term follow-up and results of the TRITON-01 study in 35 adult patientsEmmanuel Martinod, Dana M Radu, Ilaria Onorati, et al.
Pageof 9